Kala Pharmaceuticals (KALA) Price & Analysis

Compare

1,455 Followers

KALA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.92 - $11.20

Previous CloseN/A

Volume15.45K

Average Volume (3M)179.97K

Market Cap

$52.24M

Enterprise Value$28.99M

Total Cash (Recent Filing)$31.94M

Total Debt (Recent Filing)$11.14M

Price to Earnings (P/E)―

Beta1.17

Next Earnings

Nov 17, 2025

EPS Estimate

-1.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.71

Shares Outstanding7,021,040

10 Day Avg. Volume141,622

30 Day Avg. Volume179,971

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.55

Enterprise Value/Revenue114.14

Enterprise Value/Gross Profit-408.32

Enterprise Value/Ebitda-0.81

Forecast

1Y Price Target

$13.00

Price Target Upside74.73% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Analyst ConfidenceAnalyst reiterates a Buy rating and a $12 price target, suggesting confidence in the stock's future performance.

Clinical TrialsThe completion of enrollment in the Phase 2b CHASE trial for KPI-012 marks a significant step forward in the development for the treatment of persistent corneal epithelial defect (PCED).

Market OpportunityThere is no FDA-approved drug with a broad indication for all underlying etiologies of PCED, indicating a substantial market opportunity for KPI-012.

Bears Say

Clinical Trial RisksRisks include the possibility of KPI-012 failing in clinical trials, not obtaining regulatory approval, or not achieving commercial success.

Financial NeedsThe company may need to raise additional capital within the next 12 months to fund operations.

Kala Pharmaceuticals News

Kala Pharmaceuticals reports Q2 EPS ($1.71) vs ($3.16)

“The second quarter of 2025 was a pivotal period for KALA, marked by the completion of patient enrollment...

6d ago

KALA

Optimistic Buy Rating for Kala Pharmaceuticals Driven by KPI-012 Trial Prospects and Financial Viability

Kala Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from...

1d ago

KALA

Kala Pharmaceuticals Reports Q2 2025 Financial Results

Kala Pharmaceuticals ( ($KALA) ) has released its Q2 earnings. Here is a breakdown of the information Kala...

5d ago

KALA

Kala Pharmaceuticals initiated with a Buy at Ladenburg

Ladenburg initiated coverage of Kala Pharmaceuticals (KALA) with a Buy rating and $12 price target The company is...

1M ago

KALA

Promising Developments and Market Potential for Kala Pharmaceuticals’ KPI-012 Amidst Clinical and Regulatory Challenges

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Kala Pharmaceuticals today and set a price target...

1M ago

KALA

Kala Pharmaceuticals Completes Enrollment for Phase 2b Trial

Kala Pharmaceuticals ( ($KALA) ) has provided an update. On July 9, 2025, KALA BIO, Inc. announced the...

1M ago

KALA

Kala completes patient enrollment for CHASE Phase 2 clinical trial

Kala Bio announced the completion of patient enrollment in the CHASE, or Corneal Healing After SEcretome therapy, Phase...

1M ago

KALA

Kala Pharmaceuticals assumed with an Outperform at Oppenheimer

Oppenheimer assumed coverage of Kala Pharmaceuticals (KALA) with an Outperform rating and $15 price target after the company...

2M ago

KALA

Kala Pharmaceuticals price target lowered to $12 from $15 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Kala Pharmaceuticals (KALA) to $12 from $15 and keeps a...

3M ago

KALA

Kala Pharmaceuticals Advances KPI-012 in Clinical Trials

Kala Pharmaceuticals ( ($KALA) ) has released its Q1 earnings. Here is a breakdown of the information Kala...

3M ago

KALA

Kala Pharmaceuticals reports Q1 EPS ($1.41) vs ($4.20) last year

“This year, our top priority is advancing the development of KPI-012 towards key milestones,” said Todd Bazemore, interim...

3M ago

KALA

Kala Pharmaceuticals Announces Executive Retention Agreements

Kala Pharmaceuticals ( ($KALA) ) has shared an update. On April 10, 2025, Kala Pharmaceuticals, known as KALA...

4M ago

KALA

Kala Pharmaceuticals: Promising Clinical Developments and Financial Stability Support Buy Rating

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Kala Pharmaceuticals (KALA – Research Report) and...

4M ago

KALA

Kala Pharmaceuticals management to meet with Oppenheimer

Meeting to be held on April 8-10 hosted by Oppenheimer. Published first on TheFly – the ultimate source...

4M ago

KALA

KALA FAQ

What was Kala Pharmaceuticals Inc’s price range in the past 12 months?

Kala Pharmaceuticals Inc lowest stock price was $2.92 and its highest was $11.20 in the past 12 months.

What is Kala Pharmaceuticals Inc’s market cap?

Kala Pharmaceuticals Inc’s market cap is $52.24M.

When is Kala Pharmaceuticals Inc’s upcoming earnings report date?

Kala Pharmaceuticals Inc’s upcoming earnings report date is Nov 17, 2025 which is in 95 days.

How were Kala Pharmaceuticals Inc’s earnings last quarter?

Kala Pharmaceuticals Inc released its earnings results on Aug 08, 2025. The company reported -$1.71 earnings per share for the quarter, missing the consensus estimate of -$1.703 by -$0.007.

Is Kala Pharmaceuticals Inc overvalued?

According to Wall Street analysts Kala Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kala Pharmaceuticals Inc pay dividends?

Kala Pharmaceuticals Inc does not currently pay dividends.

What is Kala Pharmaceuticals Inc’s EPS estimate?

Kala Pharmaceuticals Inc’s EPS estimate is -1.22.

How many shares outstanding does Kala Pharmaceuticals Inc have?

Kala Pharmaceuticals Inc has 7,021,040 shares outstanding.

What happened to Kala Pharmaceuticals Inc’s price movement after its last earnings report?

Kala Pharmaceuticals Inc reported an EPS of -$1.71 in its last earnings report, missing expectations of -$1.703. Following the earnings report the stock price went up 3.073%.

Which hedge fund is a major shareholder of Kala Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in KALA

Kala Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-708.34%

Trailing 12-Months

Asset Growth

-41.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kala Pharmaceuticals Inc

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for eye diseases. The company primarily operates within the healthcare sector, specializing in ophthalmology. Its core products are designed to address unmet needs in ocular health, including treatments for dry eye disease and inflammation following ocular surgery.

Kala Pharmaceuticals (KALA) Earnings & Revenues

Historic Earnings Reports

KALA Stock 12 Month Forecast

Average Price Target

$13.00

▲(74.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","9":"$9","16":"$16","5.5":"$5.5","12.5":"$12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.5,9,12.5,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.5,8.076923076923077,8.653846153846153,9.23076923076923,9.807692307692307,10.384615384615383,10.961538461538462,11.538461538461538,12.115384615384615,12.692307692307692,13.269230769230768,13.846153846153847,14.423076923076923,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.5,7.923076923076923,8.346153846153847,8.76923076923077,9.192307692307692,9.615384615384615,10.038461538461538,10.461538461538462,10.884615384615385,11.307692307692307,11.73076923076923,12.153846153846153,12.576923076923077,{"y":13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.5,7.846153846153846,8.192307692307692,8.538461538461538,8.884615384615385,9.23076923076923,9.576923076923077,9.923076923076923,10.26923076923077,10.615384615384615,10.961538461538462,11.307692307692307,11.653846153846153,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.88,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.99,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.81,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.28,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.72,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.94,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.73,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >